Sign up to our daily Covid-19 newsletter for essential advice and a full summary of the day's news and developments. Register or sign in here and select Top News Stories

An experimental drug initially designed to treat Ebola could soon be used to treat coronavirus patients in a clinical trial in Australia

The broad-spectrum antiviral Remdesivir was originally developed by US drug firm Gilead to tackle the 2009 Ebola outbreak, but ultimately proved unsuccessful.

Now it's being used in several coronavirus clinical trials across the world, with some promising results.

Advertisement

Earlier this month, a 79-year-old Italian man who had tested positive to Covid-19 was cleared of the disease after taking the drug. Italian politician Giovanni Toti described it as the "first real case of coronavirus cured".

It is also being tested by the US National Institutes of Health (NIH) on 13 patients who were hospitalised after contracting Covid-19 on board the Diamond Princess cruise ship in Japan.

Remdesivir was originally developed by US drug firm Gilead to treat ebola. Photo / News Corp Australia
Remdesivir was originally developed by US drug firm Gilead to treat ebola. Photo / News Corp Australia

The World Health Organisation (WHO) has described the drug as one of the four most promising therapies, alongside the two malaria medications, Chloroquine and Hydroxychloroquine, and a combination of two HIV drugs, Lopinavir and Ritonavir.

But there is currently no stock of Remdesivir in Australia, so health authorities are hoping to have some delivered within the next 1-2 months to be trialled in some 50 hospitals.

"We are in discussions with Gilead and we want to put that in the trial as well," Professor Josh Davis, the president of the Australian Society of Infectious Diseases, told News Corp Australia.

Covid19.govt.nz: The Government's official Covid-19 advisory website

Researchers are also planning to test a TB vaccine unused in Australia since the 1980s as a potential treatment for the virus.

Murdoch Children's Research Institute will join a global trial using the tuberculosis vaccine to counter the symptoms of Covid-19.

Advertisement

The six-month trial will involve 4000 healthcare workers in Australia, lead researcher Nigel Curtis told reporters on Thursday.

Half of the workers will not be given the vaccine with researchers hoping to get some sign of its effectiveness in three months.

There have been about 2800 confirmed cases of coronavirus in Australia with 13 deaths as the country braces for the outbreak to gather pace.

Curtis said besides combating TB, the vaccine boosts the body's immune system, reducing the symptoms of coronavirus.

"It's really the first time the vaccine has been used in this way," he said. "The vaccine has the ability to 'train' the immune system to respond more strongly to infection."

He said healthcare workers were particularly vulnerable to infection, pointing to deaths of frontline workers overseas.

Similar trials are starting in the Netherlands, Germany and the UK but the Australian trial will be one of the largest.